ALK and non-small cell lung carcinoma: In this study, 358 patients diagnosed with resectable stage IB-IIIA NSCLC, lacking sensitizing mutations of EGFR and ALK, were randomized to receive histology-based chemotherapy ± nivolumab for three cycles prior to surgery.